24 Dec 2020
Posted in Pharma
Diagnosed incident cases of hepatocellular carcinoma in urban China set to rise by 44.41% over next decade, forecasts GlobalData
The diagnosed incident cases of hepatocellular carcinoma (HCC) in urban China are expected to increase by 44.41% over the next decade (2019-2029), according to GlobalData, a leading data and analytics company.
GlobalData’s latest report, ‘Hepatocellular Carcinoma – Epidemiology Forecast Report to 2029, reveals that the diagnosed incident cases of HCC are expected to increase from 0.26 million in 2019 to 0.34 million in 2029, at an annual growth rate (AGR) of 3.24% across the eight major markets 8MM*.
Of the 8MM, urban China is expected to have the highest number of diagnosed incident cases of HCC in 2029 with 0.22 million and increasing at an AGR of 4.44% (2019-2029), followed by Spain at an AGR 2.25% and the UK at an AGR 2.03%.
Suneedh Manthri, Associate Project Manager of Epidemiology at GlobalData, comments: “The major drivers for the upward trend in the diagnosed incident cases of HCC can be attributable to the increase in alcohol consumption coupled with Hepatitis B Virus (HBV) and Hepatitis V Virus (HCV) infections among men and women in the decades prior to the diagnosis of HCC.
“Urban China has the highest diagnosed incident cases of HCC among the 8MM. Urban China also has the highest diagnosed incident cases of HCC with HBV, HCV, and alcohol use as risk factors.”
*8MM: the US, France, Germany, Italy, Spain, the UK, Japan and urban China